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Abstract
Introduction: The objective of this study was to assess natural microbial agents, history and risk factors for total
joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)a-blockers, through the French
RATIO registry and a case-control study.
Methods: Cases were TJA infections during TNFa-blocker treatments. Each case was compared to two controls
(with TJA and TNFa-blocker therapy, but without TJA infection) matched on age (±15 years), TJA localization, type
of rheumatic disorder and disease duration (±15 years). Statistical analyses included univariate and multivariate
analyses with conditional logistic regression.
Results: In the 20 cases (18 rheumatoid arthritis), TJA infection concerned principally the knee (n = 12, 60%) and
the hip (n = 5, 25%). Staphylococcus was the more frequent microorganism involved (n = 15, 75%). Four patients
(20%) were hospitalized in an intensive care unit and two died from infection. Eight cases (40%) versus 5 controls
(13%) had undergone primary TJA or TJA revision for the joint subsequently infected during the last year (P =
0.03). Of these procedures, 5 cases versus 1 control were performed without withdrawing TNFa-blockers (P = 0.08).
In multivariate analysis, predictors of infection were primary TJA or TJA revision for the joint subsequently infected
within the last year (odds ratio, OR = 88.3; 95%CI 1.1-7,071.6; P = 0.04) and increased daily steroid intake (OR = 5.0
per 5 mg/d increase; 1.1-21.6; P = 0.03). Case-control comparisons showed similar distribution between TNFa-
blockers (P = 0.70).
Conclusions: In patients receiving TNFa-blockers, TJA infection is rare but potentially severe. Important risk factors
are primary TJA or TJA revision within the last year, particularly when TNFa-blockers are not interrupted before
surgery, and the daily steroid intake.
Introduction
The efficacy of TNFa blocker is now well established in
patients with rheumatoid arthritis (RA) [1], ankylosing
spondylitis (AS) [2] and psoriatic arthritis (PsA) [3].
Consequently, the prescription of these drugs becomes
more and more frequent. Their use in patients with
rheumatic disorders has led to less joint destruction and
patients’ functional prognosis has been greatly improved
[4-6]. The requirement for total joint arthroplasty (TJA)
tended to decrease in rheumatic patients before the use
of TNFa blockers in rheumatology, thanks to strategies
of earlier and more intensive management of recent
rheumatic disorders [7,8]. The use of biologic treat-
ments, and in particular of TNFa blockers, in rheumatic
disorders will probably increase this downward trend.
However, the need for TJA remains frequent, particu-
larly due to joint destructions occurring before the
introduction of TNFa blockers. Moreover, many
patients already have one or more TJA at the time of
TNFa blockers introduction.
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nistic infections in patients receiving TNFa blockers is
now well known [9,10]. An increased risk of serious bac-
terial infections in RA patients receiving TNFa blockers
has also been established through two meta-analyses of
randomized controlled trials [11,12] and retrospective
cohort studies [13,14], although other studies gave con-
tradictory results [15,16].
One of the most severe complications of TJA is surgi-
cal site infection, leading to long and expensive hospita-
lizations, complicated additional surgical procedures,
increased mortality rates and severe functional disability.
D e s p i t es y s t e m a t i cp r e v e n t i v em e a s u r e s ,t h er i s ko fT J A
infection persists and has been estimated at 1% for total
hip arthroplasty and 2% for total knee arthroplasty
[17-19]. Moreover, a two- to four-fold increased risk has
been reported in RA [20,21], although not found in
other studies [22]. The role of treatments and particu-
larly TNFa blockers in this increased risk remains
unclear [23]. Some studies concluded a similar risk of
postoperative infection after orthopedic surgery whether
the patients were exposed or not to TNFa blockers
[24-26], whereas other studies highlighted a higher risk
with TNFa blockers [27,28] reaching a two-fold increase
[28]. However, these data remain controversial.
Other identified risk factors of TJA infections are sys-
temic malignancy [29], previous prosthetic joint infec-
tion of the index joint and of any joint [21], arthroplasty
revision [21,29], increased operative time [21] and post-
operative surgical site infection not involving the arthro-
plasty [29]. Nothing is known about the relevance of
these risk factors in patients exposed to TNFa blockers.
The objectives of the present study were to evaluate
the microbial agents, natural history and risk factors of
TJA infections in patients receiving TNFa blockers,
through a case-control study.
Materials and methods
Study design
This was a case-control study including cases recruited
from a national registry (Research Axed on Tolerance of
bIOtherapies (RATIO) registry) and controls retrospec-
tively recruited from a tertiary care centre. The RATIO
registry was authorized by the ethical committee of AP-
HP, GHU Nord (Institutional Review Board of Paris
North Hospitals, Paris 7 University, AP-HP; authoriza-
tion number 162-08) [30]. Data concerning controls and
issued from their usual planned visits were collected ret-
rospectively and analyzed anonymously; no ethical
approval is necessary for this type of analysis in France
(Huriet-Sérusclat law: law n°88-1138; 20 December,
1988; published in the Journal Officiel on 22 December,
1988). Natural history of TJA infections in patients
exposed to TNFa blockers was described. To assess risk
factors of TJA infections, each case was compared with
two matched controls.
Cases
Cases had a rheumatic disorder (RA, AS, or PsA) treated
with TNFa blockers. They presented with TJA infection
while exposed to TNFa blockers or less than one year
after their withdrawal. Only TJA of large joints were
considered (hip, knee, ankle, shoulder, or elbow) what-
ever their indication (the rheumatic disorder itself,
osteoarthritis, or other cause). Each case was validated
by an expert committee; a positive culture report was
not mandatory to define TJA infection for the purposes
of this study if clinical, biologic, morphologic, or histolo-
gic features highly supported the diagnosis. Cases were
principally recruited through the national RATIO regis-
try. In this registry opportunistic infections, severe bac-
terial infections and lymphomas complicating TNFa-
blocker therapies were prospectively collected in France
between 1 February, 2004 and 31 January, 2006 [31].
Cases were self-reported by clinicians in rheumatology
departments, departments of infectious diseases, ortho-
pedic departments, and ICUs all over the country in
specific clinical research forms. Access to clinical files
was possible. To collect more cases, all infectious dis-
eases physicians from the French Society of Infectious
Diseases and 1,800 rheumatologists from French hospi-
tal centers prescribing TNFa blockers in rheumatic dis-
eases, and registered on “Club Rheumatism and
Inflammation”, a section of the French Society of Rheu-
matology were contacted through their respective web
sites [32,33], and received repeated e-mails to obtain the
files of patients with TNFa-blocker-induced TJA infec-
tion between 1 February, 2006 and 30 April, 2008. Clini-
cal data (e.g., disease activity) were collected for the
period of the diagnosis of TJA infection. Follow up was
continued at least until the end of the antibiotic treat-
ment. A 12-month follow up after TJA infection was
deemed necessary to confirm termination of the infec-
tion; otherwise the infection outcome was categorized as
unknown.
Controls
For each case, two controls were recruited, with TJA
and TNFa-blocker treatment but without TJA infection.
Prespecified matching criteria were age ±15 years, same
underlying rheumatic disorder, rheumatic disorder dura-
tion ±15 years, and same TJA localization. All was per-
formed during the selection of controls to find in our
cohort of patients for each case the two controls best
fulfilling the matching criteria. In case of peripheral
PsA, RA controls were accepted. At the beginning of
the study, no data published in the literature suggested
a different risk of infection, and particularly of
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the reason why we decided that controls would not be
required to be of the same gender as the cases. All con-
trols were retrospectively recruited in the Rheumatology
B Department in Cochin Hospital, a tertiary care center,
through a computerized search of the data files of out-
patients and inpatients between 2002 and 2008. For
each control, time of clinical data collection was chosen
for best matching of age and disease duration. The
impossibility of finding two matched controls was an
exclusion criterion of cases.
Data collection
Data abstracted from the files were noted on a standar-
dized chart review tool. In RA, rheumatic disease activ-
ity assessed by the Disease Activity Score 28 [34] was
classified as remission (<2.6), low (2.6 to 3.2), moderate
(3.2 to 5.1) and high (>5.1) activity. Considering the
definition of nosocomial TJA infections (i.e. occurring
within the 12 months after TJA setup) [35] and a med-
ian time between surgical procedure (primary TJA or
TJA revision) and TJA infection of 0.3 years (interquar-
tile range (IQR): 0.1 to 0.8) [21], primary TJA or TJA
revision within the past year on the affected or matched
joint was reported, taking into account if this surgery
had been performed before or after the introduction of
TNFa blockers. In the second situation, the patients
were considered no longer exposed to TNFa blockers at
t h et i m eo fs u r g e r yi fT N F a blockers had been with-
drawn at least five half-lives before surgery (50 days for
infliximab, 70 days for adalimumab, 15 days for
etanercept).
Statistical analysis
Statistical analyses were performed using SAS version
9.1 (SAS France, Domaine de Grégy, Grégy-sur-Yerres,
77257 Brie Comte Robert cedex, France). They included
univariate and multivariate analyses with conditional
logistic regression to take into account the matching
(PHREG procedure). All variables with a P value less
than 0.20 in univariate analysis were entered in the mul-
tivariate regression. Results achieving a P value less than
0.05 were considered as statistically significant.
Results
Cases
Twenty-two cases of TJA infection in patients treated
with TNFa blockers were collected: 13 from the RATIO
registry and 9 through the websites of the French Socie-
ties of Infectious Diseases and of the Club Rheumatism
and Inflammation. Two cases with elbow arthroplasty
infection were excluded due to lack of matched controls.
Consequently 20 cases were included in the present
case-control study (Table 1). Nineteen were female
(95%); mean age was 57.3 ± 12.4 years. Eighteen had RA
(90%). The other two cases detailed below suffered from
other rheumatic diseases. A 43-year-old woman, with
AS of 22 years’ duration and treated with infliximab,
presented an infection due to methicillin-resistant Sta-
phylococcus aureus (MRSA) on hip arthroplasty, and a
40-year-old woman, with PsA of 5 years’ duration and
treated with infliximab, presented an infection due to
methicillin-susceptible Staphylococcus aureus (MSSA)
on knee arthroplasty. Mean duration of rheumatic disor-
der was 20.4 ± 9.4 years. Seven patients received inflixi-
mab (3 mg/kg in four, 5 mg/kg in two, unknown dose
in one), five received etanercept (25 mg twice a week in
four, 50 mg once a week in one) and eight patients
received 40 mg adalimumab every other week. TJA
infections concerned the knee (n = 12, 60%), the hip (n
= 5, 25%), the shoulder (n = 2), and the ankle (n = 1).
Microbial agents
Nineteen cases (95%) had at least one positive microbio-
logical sample, i.e. hemocultures (n = 12, 60%), joint
fluid (n = 10, 50%), non surgical synovial biopsy (n =7 ,
35%), surgical biopsy (n =7 ,3 5 % )a n dd r a i n( n =2 ) .
Two files mentioned histologic findings supporting the
diagnosis of infection. In one case, no microbial agent
was identified, but the diagnosis of TJA infection was
considered as assured considering the association of an
acute access of fever and shivering, suppurating joint
fluid, C-reactive protein (CRP) level at 438 mg/L, leuko-
cytes level at 17.7 G/L, positive leukoscan and a rapid
improvement with ciprofloxacin and cloxacillin. Staphy-
lococcus was the most frequent microorganism involved
(n = 15, 75%), followed by Streptococci (n =4 :Strepto-
coccus oralis,g r o u pAStreptococcus hemolyticus,g r o u p
B Streptococcus,a n dStreptococcus salivarius), Escheri-
chia coli (n = 1) and Enterococcus (n =1 ) .S. aureus was
identified in 13 cases (65%) and was most often suscep-
tible to methicillin (n = 11, 85%). In the 12 knee arthro-
plasty infections, involved microbial agents were MSSA
in 7 cases, MSSA and Streptococcus in 1 case, MRSA
and Enterococcus in 1 case, coagulase-negative Staphylo-
coccus in 1 case, Streptococcus in 1 case and none in 1
case. In the 5 hip arthroplasty infections, they were
Streptococcus in 2 cases, MSSA in 1 case, MRSA in 1
case, and coagulase-negative Staphylococcus in 1 case.
No opportunistic infection was observed.
Natural history of TJA infection in patients exposed to
TNFa-blockers
All patients were hospitalized, 4 of them (20%) in an
ICU. Median delay from the last TNFa blocker adminis-
tration was 20 ± 68 days (30 days for infliximab, 14 days
for etanercept and 10 days for adalimumab). Symptoms
appeared suddenly in 7 cases, progressively in 8; the
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symptoms were joint pain (n = 16, 80%), swollen joint
(n = 10, 50%), fever (n = 10, 50%), shivering (n =7 ,
35%), septic shock or severe sepsis (n = 5), fistulization
(n = 2) and iterative TJA dislocation (n = 1). Nine other
infected sites were identified in 7 cases: urinary infection
(n = 2), metacarpo-phalangeal arthritis (n = 1), psoas
abscess in 1 total hip arthroplasty infection, skin infec-
tion of homolateral lower limb in 2 total knee arthro-
plasty infections, abcess of the thigh in 2 total knee
arthoplasty infections, and jugal abscess (n =1 ) .M e d i a n
CRP level was 272 mg/L (range 15 to 502). Median
polynuclear neutrophils level was 9.2 G/L (range 4.5 to
14.0). Median lymphocytes level was 0.7 G/L (range 0.2
to 2.0).
Eighteen patients underwent surgical treatment: joint
lavage (n = 11, 55%), prosthesis extraction without reim-
plantation at the time of the last news (n = 6), and two-
s t a g ea r t h r o p l a s t ye x c h a n g e( n =1 ) .O n ep a t i e n t
received only medical treatment and the type of surgical
treatment was unknown in the last patient. All cases
received antibiotic treatment: bi- or multi-antibiotic
treatment (n = 18, 90%), mono-antibiotic treatment (n =
1), not reported in one. In the 18 alive patients, median
antibiotic treatment duration in treated patients was 90
days (IQR: 45 to 146), median bi-antibiotic treatment
duration was 45 days (IQR: 42 to 112), and median
intravenous antibiotic treatment duration was 30 days
(IQR: 17 to 45).
Over a median follow-up duration of 14 months (IQR:
5 to 19), infection outcome was death in 2 cases, both
o c c u r r i n gd u r i n gt h ef i r s tm o n t h( 1 1
th and 22
nd day)
and related to infection, recovery in 11 cases (55%),
infection relapse in 1 case, and unknown in 6 patients.
In the 18 alive patients, 67% presented a rheumatic flare
(10 of 15 available data) and 7 moderate to severe func-
tional disability of the infected joint (39%). Only one
case did not experience any complication regarding the
infection outcome, rheumatic disorder outcome and
functional prognosis on the infected joint.
TNFa blockers were always withdrawn at the time of
TJA infection. In 3 patients, the same TNFa blocker
was reintroduced after the recovery from infection 3, 4.5
and 14 months, respectively, after TJA infection diagno-
sis. Infection relapse occurred in one case where the
TNFa blocker was reintroduced at 3 months. TNFa
blockers were not reintroduced in 14 cases, because the
risk of infection was considered too high (n = 12), rheu-
matic disease remission (n =1 )o rp a t i e n t ’s refusal (n =
1). The decision of reintroducing or not TNFa blockers
was unknown in the last case.
Risk factors of TJA infection in univariate analysis
Characteristics of the 20 cases (at the time of diagnosis
of TJA infection) and 40 controls (time chosen for a
best matching) are compared in Tables 1 and 2. As
expected, no difference was observed regarding match-
ing criteria (Table 1). The rheumatic disorder activity
and main comorbidities (including diabetes mellitus)
were similar in both groups. History of TJA infection
before the introduction of TNFa blockers was reported
in three cases, two involving the same joint, versus no
control (P = 0.08). Primary TJA or TJA revision for the
joint subsequently infected was performed during the
preceding year in eight (40%) cases (of which four pri-
mary TJA and three TJA revisions) versus five (13%)
controls (of which three primary TJA and two TJA revi-
sions; P = 0.03). If the majority of procedures (6/8 in
cases, and 5/5 in controls) were performed after the
introduction of TNFa blockers, the drug was withdrawn
at least five half-lives before surgery in only one of six
cases, versus four of five controls (P = 0.08). The fact
that TNFa blockers were withdrawn or not before this
surgery was not entered into the multivariate model
because this parameter only concerned the six cases and
five controls who had undergone primary TJA or TJA
Table 1 Comparison of cases † and controls* regarding matching criteria (univariate analysis with conditional logistic
regression)
Cases † (n = 20) Controls* (n = 40) P
Age (years) ** 57.3 ± 12.4 57.5 ± 10.9 0.89
RA/PsA/AS, n 18/1/1 38/0/2 0.99
Rheumatic disorder duration (years) ** 20.4 ± 9.4 20.3 ± 8.5 0.97
TJA infection localization for cases, and matched TJA localization for controls, n (%)
- Hip 5 (25) 10 (25) 1
- Knee 12 (60) 24 (60) 1
- Ankle 1 (5) 2 (5) 1
- Shoulder 2 (10) 4 (10) 1
† at the time of diagnosis of TJA infection; * time chosen for a best matching; ** mean ± standard deviation.
AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TJA, total joint arthroplasty.
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not the 20 cases and 40 controls.
Regarding anti-rheumatic treatments, only increased
daily steroid intake was significantly associated to TJA
infection (P = 0.02), but no dose threshold was identi-
fied. Non-biologic disease-modifying anti-rheumatic
drugs (DMARDs), in particular methotrexate (P =0 . 7 1 ) ,
were not significant risk factors. The distribution
between TNFa blockers was similar in cases and con-
trols (P = 0.70), but the duration of exposure to the cur-
rent TNFa blocker and to TNFa blockers in general
was longer in controls than in cases (P = 0.06 and 0.07,
respectively).
Risk factors of TJA infection in multivariate analysis
As shown in Table 3, two risk factors were identified in
multivariate analysis: steroid intake (odds ratio (OR) =
5.0 per 5 mg/day more; 1.1 to 21.6; P =0 . 0 3 )a n dp r i -
mary TJA or TJA revision for the joint subsequently
infected within the past year (OR = 88.3; 1.1 to 7,071.0;
P = 0.04).
Discussion
In the present study, TJA infection appears as a rare but
potentially severe complication of TNFa blockers. Main
risk factors are primary TJA or TJA revision for the
joint subsequently infected within the past year and
steroid intake.
Microbial agents identified in the present study were
similar to those usually observed in TJA infections in
patients having or not a rheumatic disorder
[20,29,36,37] and in RA patients not exposed to TNFa
blockers [38]. Nevertheless, most of the infections were
related to MSSA. This was more often involved than in
previous studies concerning TJA infections in patients
having or not a rheumatic disorder (22 to 45%)
[20,29,36,37], and in RA patients not exposed to TNFa
blockers (37%) [38]. No opportunistic agent was
Table 2 Comparison of the 20 cases and 40 controls in univariate analysis with conditional logistic regression
Cases (n = 20) Controls (n = 40) P
Female, n 19 34 0.27
No-low/moderate-high rheumatic disorder activity, n 11/7 20/20 0.67
TJA surgery on affected or matched joint within the last year, n 8 5 0.03†
- of which primary TJA, n/TJA revision, n 5/3 3/2
- after TNFa-blockers introduction 6 of 8 5 of 5
- after TNFa-blocker withdrawal ≥5 half-lives 1 of 6 4 of 5 0.08
Previous TJA infection, n 3 0 0.08
- of which same TJA involved, n 2 - -
Main comorbidities, n
- Diabetes mellitus 2 1 0.26
- Bronchiectasis 0 1 0.99
- Cirrhosis 0 0 1
- Cancer/hemopathy 0 2 0.99
- HIV 00 1
- Chronic renal failure 1 2 1
- Hypogammaglobulinemia 1 1 0.88
Current TNFa-blocker:
- Infliximab/etanercept/adalimumab, n 7/5/8 13/15/12 0.70
- Duration of exposition to the current TNFa- 26.0 ± 24.1 39.0 ± 24.6 0.06
blocker (months) *
Number of prior TNFa-blockers * 0.5 ± 0.7 0.6 ± 0.7 0.69
Total duration of exposition to any TNFa-blockers (months) * 32.0 ± 25.6 48.6 ± 25.2 0.07
Oral intake of steroids * (mg/d) 9.5 ± 7.3 5.3 ± 3.9 0.02†
Oral intake of steroids ≥10 mg/d, n 7 7 0.06
Intravenous infusion of steroids last year, n 2 1 0.75
Current DMARDs, n
- Methotrexate 14 26 0.71
- Leflunomide 1 5 0.99
- Azathioprine 0 2 0.40
* mean ± standard deviation; † Results achieving a P value < 0.05 were considered as statistically significant.
DMARDs, disease-modifying anti-rheumatic drugs; TJA, total joint arthroplasty; TNF, tumor necrosis factor.
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conclusions about the risk of opportunistic TJA infec-
t i o n si nt h i sp o p u l a t i o n .T N F a blockers are known to
compromise local wound healing [39], so that an
increased rate of polymicrobial infections could have
been expected; however, the rate of polymicrobial infec-
tions (n = 2, 10%) was also consistent with data from
the literature concerning TJA infections in patients hav-
ing or not a rheumatic disorder (11 to 25%) [29,36,37],
and in RA patients not exposed to TNFa blockers
(15%) [38].
This study suggests that the outcome of TJA infec-
tions is particularly severe in rheumatic patients exposed
to TNFa blockers, leading to hospitalization in an ICU
in 20% of the cases, to death in 10% and to moderate to
severe functional disability in about 40%. A high rate of
bacteremia (60%) was observed in this study compared
with 44% in a retrospective study assessing the natural
history of TJA infections in RA patients not exposed to
TNFa blockers [38]. Thus, TNFa blockers could
increase the severity of the sepsis, but further controlled
studies are needed to assess this hypothesis.
If TJA infections of large joints are often severe, their
incidence appears rare in rheumatic patients exposed to
TNFa blockers. The French national RATIO registry
identified only 13 cases over two years. However, this
study was not designed to estimate the incidence of TJA
infections in these patients. The main objective of
RATIO was to collect in an exhaustive way all over the
country two rare side effects of TNFa blockers, which
are opportunistic infections (including tuberculosis) and
lymphomas. Severe documented bacterial infections
(except pneumonias) were also collected, knowing that
it was impossible to be exhaustive. Thus, we focused on
specific types of severe infections such as TJA infections.
Taking into account the fact that septic arthritis is fre-
quent in RA, we were convinced that all cases of TJA
infection have not been declared in the RATIO registry.
B u tw h a t e v e ri ti s ,t h i ss t u d yr e p o r t i n g2 0c a s e so fT J A
infection in patients treated with TNFa blockers is to
our knowledge the largest of the literature concerning
this peculiar complication.
Actually, the herein reported case-control study was
designed to assess risk factors of TJA infection in
patients exposed to TNFa blockers. Steroids are a clas-
sic risk factor of infection in RA patients exposed
[13,16] or not [40,41] to TNFa blockers. This study
confirms this data specifically for TJA infections in
patients exposed to TNFa blockers. The fact that
patients with TJA infection had more steroids than
those without infection could also be an argument in
favor of a more severe rheumatic disorder. No threshold
of steroid intake was identified through this study, prob-
ably because of the small sample size.
Primary TJA or TJA revision within the past year was
identified as an important risk factor of subsequent
infection of this TJA. This could be due to bacterial
perioperative contamination through a hematogenous
way or a closed infected site, which is probably more
difficult to control in the case of immunomodulation by
TNFa -blockers. An infliximab-induced blood neutro-
phil deactivation has previously been demonstrated
indeed [42]. Previous studies assessing orthopedic sur-
geries failed to demonstrate that the perioperative with-
drawal of TNFa blockers reduced the risk of infection
[24,28,43]. In the present study, TNFa blockers were
less often withdrawn (stopped for more than five half-
lives) before arthroplastic surgery in cases than in
controls. This difference tended to reach statistical sig-
nificance (P = 0.08), suggesting that TNFa blocker with-
drawal could limit the infectious risk. No strong
evidence exists but prospective controlled studies are
not conceivable. In this context, withdrawal of TNFa
blockers before surgery is now highly recommended by
all societies of rheumatology and experts [14,44,45]. In
this study, we considered five half-lives since the last
administration of TNFa blockers for classifying patients
as no longer exposed to the drug at the time of surgery.
Recommended delays between last TNFa blocker
administration and orthopedic surgery depends on each
society of rheumatology. For example, the Dutch Society
for Rheumatology recommends four half-lives for each
TNFa blocker [45], whereas the French guidelines
established in 2005 recommend two weeks for etaner-
cept, and four weeks for infliximab and adalimumab
[44]. However, it is well specified in the latter guidelines
that it is a minimum and that this time has to be
increased in the case of high infectious risk surgery such
as TJA setup.
The present study suggests that a previous TJA infec-
tion before the introduction of TNFa blockers could be
a risk factor of reoccurence, although statistical signifi-
cance was not reached. In case of previous TJA infec-
tion, high reoccurence rates of TJA (10% at 3 years and
Table 3 Risk factors of TJA infection using multivariate analysis with conditional logistic regression
Variable Odds ratio 95% Confidence interval P
- Daily steroid intake (per 5 mg/day increase) 5.0 1.1 to 21.6 0.03
- Primary TJA or TJA revision for the joint subsequently infected during the last year 88.3 1.1 to 7,071.0 0.04
TJA, total joint arthroplasty.
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RA patients exposed or not to TNFa blockers, previous
surgical site infection is an identified risk factor of post-
operative infection after orthopedic surgery [43] and
after TJA [21]. Interestingly, the British Society of Rheu-
matology recommended that previous sepsis on a TJA
that remains in situ is a definitive contraindication of
TNFa blocker use [47].
Diabetes mellitus has previously been associated with
an increased risk of infection after orthopedic surgery in
RA [48]. The low number of cases (including only two
diabetic cases) in this study did not permit to confirm
this hypothesis concerning TJA infections in case of
TNFa-blocker therapy. Based on data from the litera-
ture, methotrexate does not seem to modify the risk of
postoperative infections after orthopedic surgery [48],
and particularly after TJA [43], but previous results were
heterogeneous [49,50]. Our study supports the absence
of increased risk of TJA infection if methotrexate is
added to anti-TNFa treatment. Regarding the type of
TNFa blocker, there was no significant difference
between cases and controls in our study.
The present study has several limitations and
strengths. Some potential risk factors (recent skin infec-
tion, number of previous DMARDs, cumulative steroid
intake, non-steroidal anti-inflammatory drugs) were not
assessed because of missing data in several files. Even if
it was prospective, the possible recruitment bias in the
RATIO registry has already been detailed. There were
only two Staphylococcus epidermidis infections although
w ew o u l dh a v ee x p e c t e dm o r e[ 5 1 ] .T h ec a s es e l e c t i o n
method may have led to underestimate the early less
aggressive operatively-induced infections and to recruit
the more severe hematogenous infections. The low
number of cases has limited the statistical power of the
study, and the retrospective recruitment of controls in a
single center could have led to confounding factors. At
the beginning of the study, no data published in the lit-
erature suggested a different risk of prosthetic infection
between females and males, so we decided that controls
would not be required to be of the same gender as the
cases. However, a recent study highlighted a higher risk
of revision due to deep infection on hip arthroplasty in
males than in females [42], and gender could be a con-
founding factor in our study. Controls were not selected
in the same way as cases (i.e., through a national study)
but in one center, which may induce bias. However, the
tertiary care center where controls were selected is a
referral center, therefore receiving patients having the
most severe rheumatic disorders, which we believe
selects controls close to the cases. Furthermore, the pre-
sence of a control group including two controls per
case, even if it is imperfect, increases the validity of the
results. To our knowledge, this study is the first case-
control study assessing risk factors of TJA infection in
rheumatic patients exposed to TNFa blockers.
Conclusions
TJA infection is a rare but severe complication in patients
receiving TNFa blockers. Microbial agents do not differ
from those usually identified in TJA infections, with Sta-
phylococcus species involved in most cases. Two impor-
tant modifiable risk factors have been identified: recent
TJA setup in the previous year, that is primary TJA or
TJA revision, in particular if TNFa blockers are not with-
drawn before surgery, and steroid intake.
Practical implications of this study are the following. It
may be preferable to perform arthroplasty, if needed,
before the introduction of TNFa blockers. In cases of
prosthetic surgery after the introduction of TNFa block-
ers, their withdrawal during the perioperative period is
highly recommended. Finally, steroid intake should be
reduced as low as possible in patients with both TJA
and TNFa blockers.
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